SCHEMBL3777341

SCHEMBL3777341

CC(C)c1ccc(CN2CCN(CC(=O)N3CCN(C4CCCC4)CC3)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
HTT P42858 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
GALR3 O60755 1/20 0.52
NR2F2 P24468 1/20 0.52
DRD2 P14416 2/20 0.52
DRD4 P21917 2/20 0.52
HRH3 Q9Y5N1 4/20 0.50
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
POLB P06746 2/20 0.50
FAAH O00519 1/20 0.50
ATM Q13315 1/20 0.47
GPR183 P32249 1/20 0.47
TSHR P16473 1/20 0.47
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768080 0.89 ALDH1A1 (0.57) ALDH1A1HTTSMN1; SMN2GALR3NR2F2
SCHEMBL3777226 0.88 DRD4 (0.60) ALDH1A1SMN1; SMN2DRD2DRD4HRH3
SCHEMBL23551256 0.85 ALDH1A1 (0.67) ALDH1A1HTTSMN1; SMN2GALR3NR2F2
SCHEMBL3765810 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2HRH3KMT2AKDM4E
SCHEMBL3774225 0.84 HRH3 (0.60) ALDH1A1SMN1; SMN2DRD2DRD4HRH3
SCHEMBL3765229 0.84 SCN5A (0.53) ALDH1A1DRD2DRD4HRH3KMT2A
SCHEMBL3780518 0.84 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HRH3KMT2AKDM4E
SCHEMBL26171569 0.84 ALDH1A1 (0.65) ALDH1A1HTTSMN1; SMN2GALR3NR2F2
SCHEMBL25121720 0.83 ALDH1A1 (0.64) ALDH1A1HTTSMN1; SMN2GALR3NR2F2
SCHEMBL3774090 0.81 SMN1; SMN2 (0.51) ALDH1A1HTTSMN1; SMN2HRH3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885HTT 608/4885SMN1; SMN2 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.